Im­muno­Gen gets $25M up­front for ADC ther­a­py; mi­Ra­gen adds Eu­ro­pean or­phan drug des­ig­na­tion; Pierre Fab­re buys some pre­clin­i­cal im­munother­a­pies

The Eu­ro­pean Com­mis­sion grant­ed or­phan drug des­ig­na­tion to mi­Ra­gen’s $MGEN MRG-106 for the treat­ment of cu­ta­neous T-cell lym­phoma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.